January 15, 2026

Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer?

Multimodal artificial intelligence (AI) models using a combination of molecular, imaging, and clinical features improved the individual prognostic assessment of patients with early breast cancer's ris...

The ASCO Post

January 07, 2026

AI Enhances Detection of Missed Breast Cancers on Screening Tomosynthesis

A U.S. Food and Drug Administration (FDA)​​-cleared artificial intelligence (AI) algorithm was able to detect and correctly localize almost one-third of interval breast cancers in a retrospective eval...

The ASCO Post

January 06, 2026

AI Tops Density in Predicting Breast Cancer Risk

An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a n...

The ASCO Post

October 01, 2025

Clinical Trials Unite Doctors, Researchers, and Patients to Advance Treatments

Evaluating new medical therapies in people through a rigorous, systematic process, known as a clinical trial, is the pinnacle of clinical research and the primary mechanism through which novel treatments are proven safe and effective in cancer — or any other disease.

Dana-Farber

January 02, 2026

Miami Cancer Institute Precision Oncology Symposium, Fourth Annual

This one-and-a-half-day symposium has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of solid tumors, including lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcomas and brain tumors by novel targeted agents and treatment combinations.

Baptist Health South Florida

February 10, 2021

Severity of Patients’ Symptoms May Be Underrecognized During and After Breast Radiotherapy

Physicians may commonly underrecognize radiation-associated symptoms and their severity compared with self-reports of patients with breast cancer, according to a large study comparing patient-­reporte...

The ASCO Post

January 25, 2023

SERENA-2 Trial: Camizestrant Improves Progression-Free Survival in Advanced Breast Cancer

The oral selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, as compared with fulvestrant, in previously treated postmenopausal women with advanced breast canc...

The ASCO Post

February 17, 2023

Association of Anthracycline Use With Risk of Congestive Heart Failure Among Patients Treated for Breast Cancer or Lymphoma

In a retrospective, population-based, case-control study reported in JAMA Network Open, Larsen et al found that patients receiving anthracyclines for breast cancer or lymphoma were at a significantly ...

The ASCO Post

February 06, 2023

WHO Launches New Roadmap on Breast Cancer

The World Health Organization (WHO) has released a new Global Breast Cancer Initiative Framework, providing a roadmap to attain targets to save 2.5 million lives from breast cancer by 2040. The new fr...

The ASCO Post